IONS logo

IONS
Ionis Pharmaceuticals Inc

6,659
Mkt Cap
$12.36B
Volume
4.89M
52W High
$86.15
52W Low
$23.95
PE Ratio
-45.30
IONS Fundamentals
Price
$77.53
Prev Close
$76.33
Open
$75.03
50D MA
$78.31
Beta
0.71
Avg. Volume
1.81M
EPS (Annual)
-$3.04
P/B
20.22
Rev/Employee
$659,623.95
Loading...
Loading...
News
all
press releases
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Sumitomo Mitsui Trust Group Inc.
Sumitomo Mitsui Trust Group Inc. decreased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 17.9% during the 3rd quarter, according to its most recent 13F filing...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-two ratings firms that are presently covering the company...
MarketBeat·3d ago
News Placeholder
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Pass Above 200 Day Moving Average - Should You Sell?
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Crosses Above 200 Day Moving Average - Should You Sell...
MarketBeat·4d ago
News Placeholder
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided additional updates on key milestones expected in 2026. Ionis will provide a...
Business Wire·9d ago
News Placeholder
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 44,199 Shares of Stock
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Shannon Devers sold 44,199 shares of the firm's stock in a transaction dated Wednesday, January 7th. The stock was sold at an average...
MarketBeat·11d ago
News Placeholder
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies
GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.
Zacks·12d ago
News Placeholder
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Eric Swayze Sells 23,463 Shares
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Eric Swayze sold 23,463 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average...
MarketBeat·14d ago
News Placeholder
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safety and efficacy of bepirovirsen, an...
Business Wire·14d ago
News Placeholder
Eric Swayze Sells 23,463 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Eric Swayze sold 23,463 shares of the company's stock in a transaction on Friday, January 2nd. The stock was sold at an average price...
MarketBeat·14d ago
News Placeholder
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference at...
Business Wire·15d ago
<
1
2
...
>

Latest IONS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.